Menu
Close

The conundrum

lse:fum

#21

Quite possibly, name is used else where: https://buydermamax.com/

Have to keep an eye out on: https://www.thorntonandross.co.uk/OurBrands.aspx


#22

Even if they aren’t that confident in the milestone payment for TPR I’m sure they’re pretty confident about getting some positive phase 3 data.

If they’re confident about that then they probably thought there’s no need to dilute the market even further.

On the back of positive data they should be able to do a placing at a lot higher SP if the need for a part 2.

You never know we might even get snapped up after part 1 if it’s positive.

Let’s hope the milestone payment does materialise from TPR though that would put us in a pretty strong position going forward.


#23

Just read Aberdeen’s post I crossed over what he just said


#24

The milestone payment (whilst significant compared to historical payments that FUM have had) still is no where near what FUM would need for part 2 of phase 3.

However as you say, if part 1 of phase 3 is good it puts FUM in a much stronger position for negotiating etc unlike the position we found ourselves in at the last dilution.


#25

Indeed dermamax may be used under several different guises, when FUM registered Blue Diamond there were literally loads of products with that brand name. It takes approximately 4 months for tradenames to be registered which coincidentally will be the same time TPR approval will be received.

I’m not quite sure if FUM have indicated how much part 2 will cost, maybe Aberdeen could throw some light. Also no idea what milestone amount we expect for TPR approval. Looks like Thornton & Ross paid £350k on signing the agreement in 2017, so most likely the approval should be much more.


#26

Let’s hope it at least covers some of their salaries …350k doesn’t go very far…

Depressing to see the price continue to slip, time to turn off till Summer.


#27

Approx 3 x that amount Tony so around £1 million


#28

Looking back at TPR updates and the expected timing of approval, I’ve now convinced myself that Thornton & Ross have received preliminary “positive” responses from the MHRA, possibly having to address the odd few issues (a similar carry on happened when CSD was obtaining the CE Mark approval} hence getting the ball rolling by registering “Dermamax”. All IMO of course. So I’m hoping approval will be granted very shortly. This will not only trigger a milestone payment, but could open the door to other deals outside the UK which apparently are under ongoing discussion which may resolve the Part 2 Phase 3 MED funding if further TPR licensing deals achieve decent upfront payments.

We should also be getting the Final Results for 2018 shortly (last year’s were released on 14/3/2018) but unusually no prior notification of the date as yet - FUM are usually very efficient in letting us know.


#29

Nice to see phase 3 approval in another country.

onwards and upwards with recruitment


#30

Also nice to see that SLA has gone today from a non-disclosable level (<3%) to 5.26% of shares in FUM


#31

Where?


#32

https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/FUTR/13989196.html


#33

Thank you, oddly enough on LSE website I see no RNS past 20th Feb.


#34

Unfortunately you are mistaken. If you look at your post correctly it is not futura but future plc two very different companies.


#35

Apologies, really sorry. I have both SLA and FUM in my LSE portfolio and reacted too quickly to the news item.


#36

Which is the latest country, Aberdeen? If I remember rightly, Bulgaria was the first which came before xmas. The other centres are:

I wonder if STADA are in the mix for MED. Would be a massive boost if TPR was approved if that’s the case. Again I have to jog my memory regarding previous years’ discussions but I think STADA specialise in generics. Will have to look into it again.


#37

No problem lol easily done! Had me going for a second though haha


#38

I remember last time I checked (quite recent) there were 3 countries and now there are 4.

I can’t remember which one is the most recent one.
Poland should be on there pretty soon.


#39

I think Poland’s on the list of them now unless I’m misunderstanding it.


#40

What are we expecting from mid year results then any ideas? I would imagine updates on clinical trials and possible tpr update?

Hoping this crosses the 20p mark but seems stuck at 15p